Sharsti Sandall

Executive Director, Oncology Research Pfizer

Seminars

Monday 3rd November 2025
Chair:

As ADCs become more crowded with Topo1 and MMAE payloads across oncology indications, the need for ADC differentiation across payload and targeting moieties is crucial to overcome patient resistance and provide long-term patient benefit.

Join this seminar day to stay ahead of the ADC design curve across non-cytotoxic payloads, site-specific conjugation technologies, and emerging multi payload ADC design rationale and performance

Download the Full Event Guide for full details

Sharsti Sandall- 16th World ADC San Diego